Last reviewed · How we verify
NCT06832956
Efficacy and Safety of Cryoablation with Robotic Bronchoscopy System in Patients with Lung Cancer
NA trial testing robotic bronchoscopy system in Lung Cancer Patients in 10 participants. Not yet recruiting.
31 December 2025
Quick facts
| Lead sponsor | Guangzhou Medical University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 15 February 2025 |
| Primary completion | 31 December 2025 |
| Estimated completion | 31 December 2025 |
Drugs / interventions tested
- robotic bronchoscopy system
Conditions studied
- Lung Cancer Patients — all drugs for Lung Cancer Patients →
Sponsor
Guangzhou Medical University
Who can join
Adults 18 to 75, any sex, with Lung Cancer Patients. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this single-arm clinical trial is to evaluate the safety and efficacy of robotic bronchoscopy system (RBS)-assisted cryoablation in the treatment of primary lung cancer in adult patients (aged ≥18 years) with histologically confirmed non-resectable primary lung cancer, regardless of gender. The main questions it aims to answer are: Does RBS-assisted cryoablation achieve a predefined target technical success rate for complete tumor ablation under imaging guidance? Is the incidence of severe procedure-related adverse events within an acceptable safety threshold ? Participants will: Provide written informed consent for RBS-assisted cryoablation. Undergo pretreatment evaluations, including: Multimodal imaging (CT/PET-CT) for tumor localization and staging. Pulmonary function tests and cardiopulmonary risk assessment. Receive RBS-guided cryoablation therapy under general anesthesia. Be monitored for intraoperative complications and postoperative adverse events for 72 hours. Complete follow-up assessments at 1, 3, 6, and 12 months post-procedure, including: Contrast-enhanced CT scans to evaluate local tumor control. Documentation of symptom progression and quality-of-life metrics.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06832956
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer Patients
Currently open trials in the same condition.
- NCT07281300 — Mindfulness-Oriented Respiratory Distress Symptom Intervention for Lung Cancer · NA · recruiting
- NCT07024433 — Tubeless Anesthesia in Preventing Lung Complications in Patients Undergoing Surgery for Early-Stage Lung Cancer · NA · recruiting
Other Guangzhou Medical University trials
Trials by the same sponsor.
- NCT07521618 — One-stop Diagnosis and Treatment for Suspected Lung Cancer: Combined RBS, nClE, OBCT and Ablation · NA · not yet recruiting
- NCT07352176 — Study on the Effectiveness and Safety of CLE Combined With Cryobiopsy for Diagnosis of Pulmonary Lesions · NA · not yet recruiting
- NCT06462092 — Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Canc · Phase 1, PHASE2 · recruiting
- NCT07461714 — AI-Driven Accurate Diagnosis of Pathogens in Severe Pneumonia · active not recruiting
- NCT06296745 — Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib. · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06832956 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangzhou Medical University
- Last refreshed: 18 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06832956.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing